Idéal Investisseur
Français English
CAC 40 : Market open
8 453,07 pts
+0.96%


Last updated : 27/07/2026 - 13h10
🏠 Home   ➤    Stock news

DBV Technologies Stock Falls by 2.77%, Breaking Its Support at €2.75

In mid-morning trading, the French biotech company is moving downward, contrary to a slightly declining SBF 120. The stock is now at the bottom of the index as declared short positions have increased over the past month.


DBV Technologies Stock Falls by 2.77%, Breaking Its Support at €2.75

The Stock Breaks Its €2.75 Support and Ranks Low in the SBF 120

DBV Technologies stock is down 2.77% at €2.7420 during the session, after breaking its €2.75 support earlier in the morning. It is among the largest declines in the SBF 120, while the broader index is down by 0.39%. This slide is part of an unfavorable medium-term dynamic: the stock has lost 17.66% over one month and 20.98% over three months, despite a gain of 82.56% over the past year. The price is now below its three moving averages, with a 6.73% gap below the MM20 (€2.94) and 14.58% below the MM50 (€3.21), while the RSI at 41 indicates selling pressure without a clear oversold signal. The next significant technical area on the upside remains the resistance identified at €3.36, a level around which the stock already stalled in early May after the quarterly release.

Short Positions Intensify Despite Entry into Euronext Tech Leaders

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

According to reviewed declarations, three funds now cumulatively hold 3.45% of DBV's capital sold short, up from 1.99% a month ago (+1.46 points in thirty days). This rapid increase reflects a rising bearish pressure from institutional investors, though not reaching extreme alert thresholds: the figure signals a renewed caution around the stock, to be interpreted with measure and not as an isolated verdict on its value. This comes as the company announced on June 23 its inclusion in the Euronext Tech Leaders index, effective since June 22, a recognition that has not been sufficient to halt the stock's decline. Clinically, the schedule continues to be driven by the Viaskin Peanut program, following the positive data from the phase 3 VITESSE study revealed in early June and the launch of the phase 2 THRIVE in infants. The holding of the €2.75 threshold, breached during the session, will be the immediate technical reference to watch for the continuation of the movement.



Sector Santé · Biotechnologies · Vaccins et laboratoires de recherche Biotechnologie


Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext

Context

Period
  • Period: 1T2026
Key reported figures
  • Revenue: 1M€dedollars
  • Net income: -47,6M€dedollars
  • Free cash flow: -49M€dedollars
Guidance from the release
  • Toute l'équipe de DBV démontre une focalisation et une rigueur exceptionnelles alors que nous abordons des étapes décisives au cours des prochains mois.
Risks mentioned
  • Augmentation significative des dépenses de R&D.
  • Perte nette en hausse à 47,6 millions de dollars.
Opportunities identified
  • Dépôt de la demande de licence biologique prévu pour 2026.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours